Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high-risk acute myeloid leukaemia ineligible for intensive chemotherapy (2021)

First Author: Loke J
Attributed to:  Transcriptional Regulation of GATA-1 funded by MRC


No abstract provided

Bibliographic Information

Digital Object Identifier:

PubMed Identifier: 34490623

Publication URI:

Type: Journal Article/Review

Parent Publication: British Journal of Haematology

Issue: 2

ISSN: 0007-1048